175 related articles for article (PubMed ID: 27872071)
1. Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.
Khalilieh S; Yee KL; Sanchez RI; Triantafyllou I; Fan L; Maklad N; Jordan H; Martell M; Iwamoto M
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872071
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
4. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.
Sanchez RI; Yee KL; Fan L; Cislak D; Martell M; Jordan HR; Iwamoto M; Khalilieh S
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):107-114. PubMed ID: 30973682
[TBL] [Abstract][Full Text] [Related]
7. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.
Khalilieh S; Yee KL; Liu R; Fan L; Sanchez RI; Auger P; Triantafyllou I; Stypinski D; Lasseter KC; Marbury T; Iwamoto M
J Clin Pharmacol; 2017 Jun; 57(6):777-783. PubMed ID: 28026013
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
Khalilieh S; Yee KL; Sanchez RI; Vaynshteyn K; Fan L; Searle S; Bouhajib M; Iwamoto M
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):151-161. PubMed ID: 31120195
[TBL] [Abstract][Full Text] [Related]
9. Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
Behm MO; Yee KL; Fan L; Fackler P
Antivir Ther; 2017; 22(4):337-344. PubMed ID: 28206979
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.
Behm MO; Yee KL; Liu R; Levine V; Panebianco D; Fackler P
Clin Drug Investig; 2017 Jun; 37(6):571-579. PubMed ID: 28349328
[TBL] [Abstract][Full Text] [Related]
11. Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.
Ankrom W; Yee KL; Sanchez RI; Adedoyin A; Fan L; Marbury T; Preston RA; Iwamoto M; Khalilieh SG
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891610
[TBL] [Abstract][Full Text] [Related]
12. A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.
Khalilieh SG; Yee KL; Sanchez RI; Fan L; Vaynshteyn K; Deschamps K; Martell M; Jordan HR; Iwamoto M
J Clin Pharmacol; 2019 Aug; 59(8):1093-1098. PubMed ID: 30817001
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug-Drug Interactions.
Khalilieh S; Yee KL; Sanchez R; Stoch SA; Wenning L; Iwamoto M
Clin Drug Investig; 2020 Oct; 40(10):927-946. PubMed ID: 32816220
[TBL] [Abstract][Full Text] [Related]
14. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.
Matthews RP; Jackson Rudd D; Fillgrove KL; Zhang S; Tomek C; Stoch SA; Iwamoto M
Clin Drug Investig; 2021 Jul; 41(7):629-638. PubMed ID: 34151413
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacokinetics and Drug Interactions of Doravirine.
Wilby KJ; Eissa NA
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):637-644. PubMed ID: 30047107
[TBL] [Abstract][Full Text] [Related]
18. Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Khalilieh SG; Yee KL; Sanchez RI; Fan L; Anderson MS; Sura M; Laethem T; Rasmussen S; van Bortel L; van Lancker G; Iwamoto M
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30783000
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.
Yee KL; Cabalu TD; Kuo Y; Fillgrove KL; Liu Y; Triantafyllou I; McClain S; Dreyer D; Wenning L; Stoch SA; Iwamoto M; Sanchez RI; Khalilieh SG
J Clin Pharmacol; 2021 Mar; 61(3):394-405. PubMed ID: 32989795
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1.
Yee KL; Ouerdani A; Claussen A; de Greef R; Wenning L
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
